# TAFAZZIN

## Overview
TAFAZZIN is a gene that encodes the mitochondrial enzyme tafazzin, which functions as a phospholipid-lysophospholipid transacylase. This enzyme is integral to the remodeling of cardiolipin, a crucial phospholipid in the inner mitochondrial membrane, thereby playing a vital role in maintaining mitochondrial membrane integrity and function. Tafazzin is part of a superfamily of acyltransferases and is characterized by its involvement in the redistribution of fatty acids among phospholipids, which is essential for mitochondrial dynamics and energy production (Schlame2020The; Ren2014Metabolism). Mutations in the TAFAZZIN gene are linked to Barth syndrome, a rare genetic disorder that affects mitochondrial function, highlighting the clinical significance of this gene and its encoded protein (Kutschka2023Activation; Pang2022Barth).

## Structure
The tafazzin protein, encoded by the TAFAZZIN gene, is a mitochondrial phospholipid-lysophospholipid transacylase involved in cardiolipin remodeling. Although its crystal structure has not been determined, structural prediction algorithms suggest the presence of a 21 amino acid transmembrane domain in the N-terminal region, encoded by exon 1, and a catalytic HX4D motif in exon 2 (Chin2020Role). Tafazzin also features a 57 amino acid substrate-binding cleft spanning multiple exons, including exons 2, 4, 6, 7, 8, and 10 (Chin2020Role). This cleft contains conserved, positively charged residues crucial for phospholipid binding (Garlid2020TAZ).

Tafazzin is part of a superfamily of acyltransferases and is characterized by a conserved hydrophobic segment near the N terminus, which is important for mitochondrial targeting (Schlame2020The). The protein does not have a canonical targeting signal but interacts with the Tim9-Tim10 complex for mitochondrial membrane insertion (Schlame2020The). Tafazzin exists in multiple splice variant isoforms, with the dominant human form lacking exon 5, which remains active and functional in mitochondria (Schlame2020The). These structural features are essential for its role in cardiolipin remodeling and mitochondrial function.

## Function
TAFAZZIN is a mitochondrial enzyme that plays a crucial role in the remodeling of cardiolipin (CL), a key phospholipid in the inner mitochondrial membrane. This enzyme functions as a phospholipid-lysophospholipid transacylase, facilitating the exchange of acyl groups between CL and other phospholipids, a process essential for maintaining the proper composition and abundance of CL in healthy human cells (Schlame2020The; Ren2014Metabolism). The remodeling of CL by TAFAZZIN is vital for mitochondrial membrane dynamics, including membrane fusion and the formation of membrane folds, which are critical for mitochondrial function and energy production (Ren2014Metabolism).

TAFAZZIN's activity is linked to the redistribution of fatty acids among phospholipids, impacting the membrane lipid composition and stabilizing CL by creating a stable physical state of mitochondrial lipids (Schlame2020The). This stabilization is particularly important in tissues with high-energy demands, as it helps accommodate a high density of proteins in the mitochondrial inner membrane, reducing the energy cost of membrane assembly and allowing for higher ATP production rates (Schlame2020The). The enzyme's ability to react with a broad spectrum of phospholipid classes and fatty acids indicates a complex mechanism that may be influenced by the physical properties of membranes (Schlame2020The).

## Clinical Significance
Mutations in the TAFAZZIN gene are primarily associated with Barth syndrome (BTHS), a rare X-linked genetic disorder. BTHS is characterized by cardiomyopathy, skeletal muscle weakness, neutropenia, and growth retardation. The condition is caused by defects in the mitochondrial transacylase TAFAZZIN, which is crucial for the remodeling of cardiolipin, a key phospholipid in mitochondrial membranes. These mutations lead to an abnormal cardiolipin profile, resulting in mitochondrial dysfunction, impaired energy production, and increased susceptibility to infections due to neutropenia (Kutschka2023Activation; Pang2022Barth; Garlid2020TAZ).

The clinical manifestations of Barth syndrome can vary significantly, even among patients with the same TAFAZZIN variant. This variability is partly due to differences in the physiological modifiers that influence the severity of the disease. Elevated levels of reactive oxygen species (ROS) have been observed in BTHS models, suggesting that oxidative stress may contribute to the pathogenesis of the disorder (Liang2022Current). Despite the mitochondrial dysfunction, some compensatory mechanisms, such as increased mitochondrial mass, are observed in patient cells to maintain ATP production (Gonzalvez2013Barth).

## Interactions
TAFAZZIN, a phospholipid-lysophospholipid transacylase, plays a crucial role in mitochondrial function through its interactions with various proteins. It is involved in the remodeling of cardiolipin, a key phospholipid in the inner mitochondrial membrane, which is essential for the structural and functional integrity of mitochondrial proteins and complexes. TAFAZZIN interacts with the Tim9-Tim10 complex in the intermembrane space, facilitating its import into mitochondria and subsequent insertion into the inner membrane (Schlame2020The).

TAFAZZIN is also associated with the stabilization of mitochondrial respiratory supercomplexes, which are crucial for efficient oxidative phosphorylation. Its deficiency leads to destabilization of these supercomplexes, highlighting its role in maintaining mitochondrial membrane integrity and function (Chin2020Role). The enzyme's activity is linked to the reacylation of monolysocardiolipin to mature cardiolipin, using phosphatidylcholine as an acyl donor, which is vital for the proper assembly and function of mitochondrial complexes (Xu2006The).

In the context of Barth syndrome, TAFAZZIN deficiency results in increased oxidative stress and altered interactions with proteins involved in apoptosis, such as caspase-8 and Bid, due to the absence of mature cardiolipin at mitochondrial contact sites (Petit2020Tafazzin). These interactions underscore the enzyme's importance in mitochondrial quality control and cellular stress responses.


## References


[1. (Kutschka2023Activation) Ilona Kutschka, Edoardo Bertero, Christina Wasmus, Ke Xiao, Lifeng Yang, Xinyu Chen, Yasuhiro Oshima, Marcus Fischer, Manuela Erk, Berkan Arslan, Lin Alhasan, Daria Grosser, Katharina J. Ermer, Alexander Nickel, Michael Kohlhaas, Hanna Eberl, Sabine Rebs, Katrin Streckfuss-Bömeke, Werner Schmitz, Peter Rehling, Thomas Thum, Takahiro Higuchi, Joshua Rabinowitz, Christoph Maack, and Jan Dudek. Activation of the integrated stress response rewires cardiac metabolism in barth syndrome. Basic Research in Cardiology, November 2023. URL: http://dx.doi.org/10.1007/s00395-023-01017-x, doi:10.1007/s00395-023-01017-x. This article has 6 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00395-023-01017-x)

[2. (Liang2022Current) Zhuqing Liang, Michael W. Schmidtke, and Miriam L. Greenberg. Current knowledge on the role of cardiolipin remodeling in the context of lipid oxidation and barth syndrome. Frontiers in Molecular Biosciences, May 2022. URL: http://dx.doi.org/10.3389/fmolb.2022.915301, doi:10.3389/fmolb.2022.915301. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2022.915301)

[3. (Gonzalvez2013Barth) François Gonzalvez, Marilena D’Aurelio, Marie Boutant, Aoula Moustapha, Jean-Philippe Puech, Thomas Landes, Laeticia Arnauné-Pelloquin, Guillaume Vial, Nellie Taleux, Christian Slomianny, Ronald J. Wanders, Riekelt H. Houtkooper, Pascale Bellenguer, Ian Max Møller, Eyal Gottlieb, Frederic M. Vaz, Giovanni Manfredi, and Patrice X. Petit. Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (taz) gene mutation. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1832(8):1194–1206, August 2013. URL: http://dx.doi.org/10.1016/j.bbadis.2013.03.005, doi:10.1016/j.bbadis.2013.03.005. This article has 134 citations.](https://doi.org/10.1016/j.bbadis.2013.03.005)

[4. (Chin2020Role) Michael T. Chin and Simon J. Conway. Role of tafazzin in mitochondrial function, development and disease. Journal of Developmental Biology, 8(2):10, May 2020. URL: http://dx.doi.org/10.3390/jdb8020010, doi:10.3390/jdb8020010. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/jdb8020010)

[5. (Petit2020Tafazzin) Patrice Petit, Hector Ardilla-Osorio, Lucile Penalvia, and Nathan E. Rainey. Tafazzin mutation affecting cardiolipin leads to increased mitochondrial superoxide anions and mitophagy inhibition in barth syndrome. Cells, 9(10):2333, October 2020. URL: http://dx.doi.org/10.3390/cells9102333, doi:10.3390/cells9102333. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells9102333)

[6. (Ren2014Metabolism) Mindong Ren, Colin K.L. Phoon, and Michael Schlame. Metabolism and function of mitochondrial cardiolipin. Progress in Lipid Research, 55:1–16, July 2014. URL: http://dx.doi.org/10.1016/j.plipres.2014.04.001, doi:10.1016/j.plipres.2014.04.001. This article has 256 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.plipres.2014.04.001)

[7. (Schlame2020The) Michael Schlame and Yang Xu. The function of tafazzin, a mitochondrial phospholipid–lysophospholipid acyltransferase. Journal of Molecular Biology, 432(18):5043–5051, August 2020. URL: http://dx.doi.org/10.1016/j.jmb.2020.03.026, doi:10.1016/j.jmb.2020.03.026. This article has 35 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2020.03.026)

[8. (Garlid2020TAZ) Anders O. Garlid, Calvin T. Schaffer, Jaewoo Kim, Hirsh Bhatt, Vladimir Guevara-Gonzalez, and Peipei Ping. Taz encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of barth syndrome. Gene, 726:144148, February 2020. URL: http://dx.doi.org/10.1016/j.gene.2019.144148, doi:10.1016/j.gene.2019.144148. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gene.2019.144148)

[9. (Pang2022Barth) Jing Pang, Yutong Bao, Kalia Mitchell-Silbaugh, Jennifer Veevers, and Xi Fang. Barth syndrome cardiomyopathy: an update. Genes, 13(4):656, April 2022. URL: http://dx.doi.org/10.3390/genes13040656, doi:10.3390/genes13040656. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes13040656)

[10. (Xu2006The) Yang Xu, Ashim Malhotra, Mindong Ren, and Michael Schlame. The enzymatic function of tafazzin. Journal of Biological Chemistry, 281(51):39217–39224, December 2006. URL: http://dx.doi.org/10.1074/jbc.m606100200, doi:10.1074/jbc.m606100200. This article has 265 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m606100200)